文献速递慢性静脉疾病

大隐静脉直径与腔内消融疗效及安全性的分层比较

Effect of endovenous ablation assessment stratified by great saphenous vein size, gender, clinical severity, and patient-reported outcomes.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-04-27

两组术后VCSS与HASTI症状评分均改善且改善程度相似,但≥5 mm组并发症、术后抗凝、部分再通及误工天数更多。作者认为不应以静脉直径限制干预或医保覆盖。

要点

  • GSV直径<5 mm与≥5 mm患者消融后症状改善程度相似。
  • GSV≥5 mm组术后并发症、抗凝及部分再通比例更高。
  • 不应以术前GSV直径作为拒绝干预或医保覆盖的理由。

核心结论

  • 无论GSV直径大小,腔内消融后临床结局与患者报告结局均改善。
  • GSV≥5 mm患者症状改善程度相似但并发症发生率增加。
  • 不应因静脉直径较小而拒绝干预或医保覆盖。

研究设计与样本

  • 前瞻性纳入国家队列VQI Varicose Vein Registry数据库。
  • 按GSV直径分层比较CEAP分级、VCSS与患者报告结局,采用两样本Wilcoxon检验及配对Wilcoxon符号秩检验。

主要发现

  • 两组血肿发生率相似,<5 mm组感觉异常发生率更高。
  • 两组VCSS与HASTI评分均改善,症状改善程度相似。

关键数值与推荐

  • GSV直径分组界值为5 mm(<5 mm为组1,≥5 mm为组2)。
  • 两组均无死亡发生。

临床怎么用

  • 对GSV直径<5 mm的有症状患者,不应仅凭直径拒绝腔内消融或医保覆盖。
  • GSV≥5 mm患者术后应更关注并发症、抗凝需求、再通及误工情况。

局限性

  • 原文摘要未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The policies of insurance carriers have used the truncal vein size as a criterion for coverage. The objective of the present study was to compare the effect of great saphenous vein (GSV) size ≥5 mm vs <5 mm on patient presentation and clinical outcomes. METHODS: Patients in a national cohort were prospectively captured in the Vascular Quality Initiative Varicose Vein Registry. From January 2015 to October 2017, the Vascular Quality Initiative Varicose Vein Registry database was queried for all patients who had undergone varicose vein procedures. The CEAP (clinical, etiologic, anatomic, pathophysiologic) classification, Venous Clinical Severity Score, and patient-reported outcomes were compared by GSV size (<5 mm, group 1; ≥5 mm, group 2) before and after the procedures. A 2-sample Wilcoxon test was performed to assess the differences between the 2 groups stratified by GSV size. To assess for postoperative improvement, a matched-pairs Wilcoxon signed rank test was performed for each group separately. RESULTS: During the study period, 5757 vein ablation procedures had been performed for GSV: 770 for GSV size <5 mm and 4987 for GSV size ≥5 mm. Patients in group 1 were more likely to be women (81.7% vs 68.4%; P = .001) and older (56.8 vs 55.6 years; P = .012). The CEAP clinical class was more advanced in group 2 than in group 1 (P = .001). The maximal GSV diameter in group 2 was significantly greater than in group 1 (8.32 vs 3.86 mm; P = .001); 64% of group 2 and 59.2% of group 1 had undergone radiofrequency thermal ablation (P = .001). No mortalities occurred in either group. Group 2 had more complications postoperatively (0.6% vs 0%; P = .027), required postoperative anticoagulation (8.8% vs 5%, P = .001), developed partial recanalization (0.8% vs 0.3%; P = .001), and missed more work days (2.32 vs 1.6 days) compared with group 1. A similar rate of hematoma developed in both groups, but group 1 had a higher rate of paresthesia. Both groups had improvement in the Venous Clinical Severity Score and HASTI (heaviness, achiness, swelling, throbbing, itching) score. The degree of symptomatic improvement between the 2 groups was similar. CONCLUSIONS: All patients demonstrated improvement in both clinical outcomes and patient-reported outcomes after endovenous ablation, regardless of GSV size. Patients with a preoperative GSV size ≥5 mm experienced similar improvement in symptoms but an increased complication rate. Patients with a smaller vein size should not be denied intervention or coverage by vein size.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Bendix SD, Peterson EL, Kabbani LS, et al. Effect of endovenous ablation assessment stratified by great saphenous vein size, gender, clinical severity, and patient-reported outcomes. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32353593. doi:10.1016/j.jvsv.2020.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。